video1.0<iframe src="https://www.loom.com/embed/df12d244e18743b0a2c01fd19ffff9ce" frameborder="0" width="1920" height="1440" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>14401920Loomhttps://www.loom.com14401920https://cdn.loom.com/sessions/thumbnails/df12d244e18743b0a2c01fd19ffff9ce-7b43adf20b4e19b1.gif84.287Hi there, I'm Brock Schumann, CEO of Azore Biotech, and I'm excited to share how we are revolutionizing AI drug design by using living biology. We analyze 10,000 zebrafish a week to train our platform with advanced imaging and multi-omic data. This year, we're projected to generate 6.5 million in revenue as a cash-positive CRO, and we are seeking funds to expand our market reach and develop our own therapeutics. With a strong acquisition interest in our technology, we are well-positioned for growth, especially with our CEO Lubos Marek's impressive track record. If you are interested in joining us by closing the last half million of our seed round, please take a look at our safe.